中华肝脏病杂志
中華肝髒病雜誌
중화간장병잡지
CHINESE JOURNAL OF HEPATOLOGY
2013年
4期
271-274
,共4页
滕晓英%周新刚%孙磊%王鹏%王泰龄
滕曉英%週新剛%孫磊%王鵬%王泰齡
등효영%주신강%손뢰%왕붕%왕태령
肝炎,慢性%肝硬化%分期标准
肝炎,慢性%肝硬化%分期標準
간염,만성%간경화%분기표준
Chronic hepatitis%Liver cirrhosis%Fibrosis stage system
目的 细化慢性肝炎肝纤维化分期标准,并检测其在药物疗效判定中的有效性和敏感性. 方法 严格参照指南推荐标准,制定细化的分期标准并绘制模式图;分别按照指南推荐标准和细化标准对396例肝穿刺活组织标本进行纤维化分期判读.按照指南推荐标准药物治疗前后病例分布差异用x2检验进行分析;按照细化标准得到的治疗前后纤维化分期的差异进行赋值后,采用配对t检验进行比对,采用SPSS软件完成. 结果 参照指南推荐标准,治疗前后纤维化分期的改变不具有统计学意义,x2=3.144,P=0.534;按照细化标准,治疗前后纤维化分期的改变具有统计学意义,6.55±2.93对比6.19±2.945,P<0.01.结论 细化标准在药物疗效评定中有效,且较指南推荐标准对于药物疗效的评定具有更好的敏感性.
目的 細化慢性肝炎肝纖維化分期標準,併檢測其在藥物療效判定中的有效性和敏感性. 方法 嚴格參照指南推薦標準,製定細化的分期標準併繪製模式圖;分彆按照指南推薦標準和細化標準對396例肝穿刺活組織標本進行纖維化分期判讀.按照指南推薦標準藥物治療前後病例分佈差異用x2檢驗進行分析;按照細化標準得到的治療前後纖維化分期的差異進行賦值後,採用配對t檢驗進行比對,採用SPSS軟件完成. 結果 參照指南推薦標準,治療前後纖維化分期的改變不具有統計學意義,x2=3.144,P=0.534;按照細化標準,治療前後纖維化分期的改變具有統計學意義,6.55±2.93對比6.19±2.945,P<0.01.結論 細化標準在藥物療效評定中有效,且較指南推薦標準對于藥物療效的評定具有更好的敏感性.
목적 세화만성간염간섬유화분기표준,병검측기재약물료효판정중적유효성화민감성. 방법 엄격삼조지남추천표준,제정세화적분기표준병회제모식도;분별안조지남추천표준화세화표준대396례간천자활조직표본진행섬유화분기판독.안조지남추천표준약물치료전후병례분포차이용x2검험진행분석;안조세화표준득도적치료전후섬유화분기적차이진행부치후,채용배대t검험진행비대,채용SPSS연건완성. 결과 삼조지남추천표준,치료전후섬유화분기적개변불구유통계학의의,x2=3.144,P=0.534;안조세화표준,치료전후섬유화분기적개변구유통계학의의,6.55±2.93대비6.19±2.945,P<0.01.결론 세화표준재약물료효평정중유효,차교지남추천표준대우약물료효적평정구유경호적민감성.
Objective To generate a refined staging system of fibrosis in chronic viral hepatitis and to assess its accuracy and sensitivity for evaluating therapeutic efficacy of anti-fibrosis drug treatments.Methods A refined fibrosis staging system was established according to the detailed characteristics of progressive fibrosis.A total of 396 liver puncture biopsy specimens were collected from patients before and after anti-fibrosis therapy and used to evaluate the refined staging system.According to the original fibrosis staging system and refined fibrosis staging system,fibrosis staging differences from before and after treatment were analyzed by Chi-squared test and paired-samples t-test respectively.Results The refined fibrosis staging system detected significant changes in fibrosis stage that occurred in response to treatment (before treatment:6.55 ± 2.93 vs.after treatment:6.19 ± 2.945,P < 0.01).However,the original (unrefined) staging system was unable to differentiate therapy-related changes in fibrosis stage (x2 =3.144,P =0.534).Conclusion The newly-developed refined fibrosis staging system was able to effectively evaluate the therapeutic efficacy of anti-fibrosis drug treatment and performed better than the original staging system.